leisure time -WSS

leisure time

author：fashion 2025-10-02 12:01:43 - browse：64

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： For longer

Wikipedia

focus

WSS

Carbon Health diabetes program, a test of data

What is STAT's opinion section for?

First transplant of an entire human eye performed

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

entertainment

leisure time

hotspot

Peter Hotez and the public health issue of online harassment

Making the case for fair compensation in clinical trials

Wildfire smoke exposes gaps in outdoor worker protections

First transplant of an entire human eye performed

How one medical school became remarkably diverse

Ventyx halts psoriasis drug development after lackluster trial results

Medicare details structure of new drug price negotiation program

Scrutiny of post

23andMe had bad news about my health. I wish a person had delivered it

Medical school prerequisites are outdated

Wikipedia

Publishing genetic code of viruses could cause disaster

Fentanyl is making it harder to start addiction treatment

For longer

Scrutiny of post

Medicare’s new pay boost for primary care is angering specialists

Making the case for fair compensation in clinical trials

Wikipedia

Wikipedia

focus

Wikipedia